Myeloma Investment Fund Invests in Nectin Therapeutics to Evaluate Nectin’s Anti-PVR Lead Drug Candidate as a Treatment for Multiple Myeloma


Nectin Therapeutics, a biotechnology company developing novel targeted immunotherapies to address tumor immune resistance, and the Myeloma Investment Fund (MIF), the Multiple Myeloma Research Foundation’s (MMRF) venture philanthropy subsidiary, today announced that the MIF has invested in Nectin Therapeutics to explore the potential of NTX1088, Nectin’s first-in-class lead immunotherapy drug candidate, for the treatment of multiple myeloma.

“We look forward to our partnership with Nectin Therapeutics to evaluate NTX1088 as a potential therapy for multiple myeloma,” said Michael Andreini, President and Chief Executive Officer of the Multiple Myeloma Research Foundation. “The MIF is committed to identifying and accelerating the most innovative treatment approaches for myeloma patients. We are pleased to support this first-in-class antibody targeting PVR based on the potential to overcome immune evasion and enhance the immune system’s response against myeloma.”

“We are delighted to join forces with the Myeloma Investment Fund, allowing us to collaborate and explore the potential of our lead candidate, NTX1088, in the treatment of multiple myeloma,” said Fabian Tenenbaum, Chief Executive Officer of Nectin. “NTX1088 is currently being studied in patients with advanced and metastatic solid tumors, and we look forward to working closely with the MIF to uncover the role that PVR blockade may serve in addressing the unmet needs of myeloma patients.”

Together with the MIF’s investment, Nectin has raised over $33M supported by investments from aMoon, Peregrine Ventures, Israel Biotech Fund, Cancer Focus Fund and Integra Holdings.

Related Videos
Kristie L. Kahl and Mary Derome
Kristie L. Kahl and Amy Pierre
Kristie L. Kahl and Dr. Nina Shah
Kristie L. Kahl and Dr. Hearn J. Cho
Kristie L. Kahl and Dr. Irene Ghobrial